| Median rating (30th to 70th percentiles)‡ | Disagreement index§ | |
| Adverse effects of intervention* | 1 (1 to 2) | 0.22 |
| Serum urate* | 1 (1 to 1) | 0 |
| Gout flare recurrence* | 1 (1 to 1) | 0 |
| Tophus regression* | 2 (2 to 2) | 0 |
| Health-related quality of life* | 2 (1.6 to 3) | 0.41 |
| Pain | 2 (1 to 2.4) | 0.33 |
| Patient global* | 2 (1 to 2) | 0.22 |
| Physician global | 2 (1 to 3) | 0.52 |
| Work disability (absentee-ism or presentee-ism) | 2 (2 to 3) | 0.32 |
| Joint inflammation | 2 (2 to 4) | 0.85 |
| Physical function*† | ||
| Functional disability (difficulty with daily activities) | 2 (1 to 3) | 0.52 |
| Joint impairment (loss of joint motion) | 3 (2 to 3) | 0.32 |
| Joint damage imaging* | 3 (3 to 4) | 0.32 |
| Participation (life-role)* | 3 (2 to 4) | 0.85 |
| Health care utilisation | 3 (3 to 3) | 0 |
| Costs | 3 (3 to 4) | 0.32 |
| Patient utility (value of current health state) | 3 (2 to 3) | 0.32 |
| Comorbidities | 3 (2 to 4) | 0.85 |
| Acute phase marker | 4 (3 to 5) | 0.52 |
| Total body urate pool | 5 (3.4 to 6) | 0.53 |
| Impact on family | 5 (4 to 6) | 0.37 |
| Absence of urate crystals from knee synovial fluid | 5 (4 to 6) | 0.37 |
| Depression | 6 (4 to 6) | 0.37 |
*Domain recommended by OMERACT SIG.
†This item was rated highly in the first iteration (median 2) but respondents requested more precise clarification of meaning for subsequent iterations.
‡Ratings of 1–3 indicate item should be included in studies of gout; 4 indicates uncertainty; 5–7 indicate item should not be included in studies of gout.
§A disagreement index of less than 1 indicates no disagreement.10